sulfasalazine and Bowel Diseases, Inflammatory studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research Excerpts

Excerpt	Relevance	Reference
"Mesalamine (5-ASA) is one of the drugs indicated as first line therapy in ulcerative colitis for induction and maintenance of remission."	7.83	Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. ( Kandula, M; Palanichamy, S; Rampal, A; Sunil Kumar, KB, 2016)
"This observation suggests that the higher frequency of lymphopenia may be associated with the elevated 6-TGN concentrations recovered in patients treated with aminosalicylates."	7.76	High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. ( Boulieu, R; Lachaux, A; Le Gall, C; Nguyen, TM, 2010)
" In patients with inflammatory bowel diseases, the use of 5-aminosalicylic acid or sulfasalazine was not associated with increased risk of acute pancreatitis."	7.72	Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. ( Floyd, A; Munk, EM; Nørgård, B; Pedersen, L; Rasmussen, HH; Sørensen, HT, 2004)
"We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy."	7.71	Population-based case control study of the safety of sulfasalazine use during pregnancy. ( Czeizel, AE; Nørgård, B; Olsen, J; Rockenbauer, M; Sørensen, HT, 2001)
"DSS was used to induce intestinal inflammation in conventional Balb/c mice and athymic nu/nu CD-1(BR) mice, and the well-documented 5-aminosalicylic acid (5-ASA) based anticolitis drugs sulphasalazine (SASP) and olsalazine (OLZ) were used to study therapeutic effects."	7.70	Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. ( Axelsson, LG; Bylund-Fellenius, AC; Landström, E, 1998)
"The efficacy of zileuton, a new 5-lipoxygenase inhibitor, was investigated in comparison with sulphasalazine in an experimental model of rat colitis."	7.68	Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. ( Camerini, R; Caputi, AP; Graziani, P; Squadrito, F; Zingarelli, B, 1993)
" Because sulfasalazine presents serious side effects through long-term use at high doses, the aim of the present study was to evaluate the preventative effect of polydextrose on trinitrobenzenesulfonic acid-induced intestinal inflammation and its effects on the intestinal anti-inflammatory activity of sulfasalazine."	5.36	Dietary polydextrose prevents inflammatory bowel disease in trinitrobenzenesulfonic acid model of rat colitis. ( Di Stasi, LC; Fruet, AC; Salem, L; Witaicenis, A, 2010)
"Twenty-four patients with spondylitis and Crohn's disease or ulcerative colitis, treated with 5-ASA or sulfasalazine, were randomised and assessed by an investigator independent from the spa staff: 12 were submitted to a cycle of mud-bath treatment (12 mud packs and 12 thermal baths over a period of two weeks) and 12 were enrolled as controls."	5.12	Mud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trial. ( Cardinale, G; Cozzi, F; Dani, L; Oliviero, F; Podswiadek, M; Punzi, L; Sfriso, P, 2007)
"Sulfasalazine (SASP) is a drug commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA)."	4.87	Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. ( Alonso, V; Domingo, JL; Linares, V, 2011)
"Three patients with reactive arthritis and 2 with ankylosing spondylitis resistant to therapy with nonsteroidal antiinflammatory drugs were treated with enteric coated sulfasalazine in an open trial."	4.77	Treatment of the seronegative spondyloarthropathies with sulfasalazine. ( Comer, SS; Erdman, WA; Lee, E; Lipsky, PE; Zwillich, SH, 1988)
" Tofacitinib is a Janus kinase inhibitor approved for treating rheumatoid arthritis and ulcerative colitis."	4.31	Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. ( Haq, SA; Momen Majumder, MS; Rasker, JJ, 2023)
" The aim of this study was to evaluate the effect of AMFJ in a rat TNBSinduced colitis model and to compare the effect of the juice with that of sulfasalazine."	3.88	Aronia melanocarpa fruit juice ameliorates the symptoms of inflammatory bowel disease in TNBS-induced colitis in rats. ( Kuzmanov, A; Kuzmanova, V; Tzaneva, M; Valcheva-Kuzmanova, S, 2018)
"Sulfasalazine is a commonly used drug for the treatment of rheumatoid arthritis and inflammatory bowel disease."	3.85	Sulfasalazine induces mitochondrial dysfunction and renal injury. ( Abdoli, N; Asadi, B; Azarpira, N; Heidari, R; Khodaei, F; Mohammadzadeh, R; Najibi, A; Niknahad, H; Ommati, MM; Rasti, M; Saeedi, A; Shirazi Yeganeh, B; Taheri, V; Zarei, M, 2017)
" The strong inhibitory activity of compound 55 against an in vivo colitis model was confirmed by its dose-dependent inhibitory activity in a rat model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis, demonstrating compound 55 as a new potential candidate for the development of therapeutics against IBD."	3.85	Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease. ( Banskota, S; Bist, G; Gurung, P; Kadayat, TM; Kim, JA; Lee, ES; Shrestha, A; Thapa Magar, TB, 2017)
" The fruit extract (50, 100 and 200mg/kg) treated enterocolitis rats significantly retain their body weight, organ weight, stool consistency, macroscopic score, histology, haematological parameters, antioxidative enzyme levels and also reduce the serum marker levels and myeloperoxidase (MPO) activity compared to prednisolone (2mg/kg) and sulfasalazine (50mg/kg) drugs."	3.85	Study of intestinal anti-inflammatory activity of Phoenix loureiroi Kunth (Arecaceae) fruit. ( Murugan, R; Parimelazhagan, T; Saravanan, S, 2017)
"Mesalamine (5-ASA) is one of the drugs indicated as first line therapy in ulcerative colitis for induction and maintenance of remission."	3.83	Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. ( Kandula, M; Palanichamy, S; Rampal, A; Sunil Kumar, KB, 2016)
"Earlier studies showed that the compatible solute ectoine (1) given prophylactically before induction of colitis by 2,4,6-trinitrobenzenesulfonic acid (TNBS) in rats prevented histological changes induced in the colon and the associated rise in inflammatory mediators."	3.81	Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease. ( Abdel-Aziz, H; Efferth, T; Khayyal, MT; Scherner, O; Wadie, W, 2015)
"This observation suggests that the higher frequency of lymphopenia may be associated with the elevated 6-TGN concentrations recovered in patients treated with aminosalicylates."	3.76	High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. ( Boulieu, R; Lachaux, A; Le Gall, C; Nguyen, TM, 2010)
" The prodrugs exhibited comparable ameliorating effect as that of sulfasalazine on trinitrobenzenesulfonic acid-induced experimental colitis in rats with a better safety profile."	3.75	Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. ( Bhatt, L; Dhaneshwar, SS; Gairola, N; Kadam, SS; Kandpal, M; Rathi, B; Vadnerkar, G, 2009)
" In patients with inflammatory bowel diseases, the use of 5-aminosalicylic acid or sulfasalazine was not associated with increased risk of acute pancreatitis."	3.72	Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. ( Floyd, A; Munk, EM; Nørgård, B; Pedersen, L; Rasmussen, HH; Sørensen, HT, 2004)
"We found no significant increased prevalence of selected congenital abnormalities in the children of women treated with sulfasalazine during pregnancy."	3.71	Population-based case control study of the safety of sulfasalazine use during pregnancy. ( Czeizel, AE; Nørgård, B; Olsen, J; Rockenbauer, M; Sørensen, HT, 2001)
"DSS was used to induce intestinal inflammation in conventional Balb/c mice and athymic nu/nu CD-1(BR) mice, and the well-documented 5-aminosalicylic acid (5-ASA) based anticolitis drugs sulphasalazine (SASP) and olsalazine (OLZ) were used to study therapeutic effects."	3.70	Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. ( Axelsson, LG; Bylund-Fellenius, AC; Landström, E, 1998)
"Sulfasalazine is widely used in rheumatoid arthritis and inflammatory bowel diseases."	3.69	Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. ( Pruzanski, W; Ramamurthy, NS; Stefanski, E; Vadas, P, 1997)
"The efficacy of zileuton, a new 5-lipoxygenase inhibitor, was investigated in comparison with sulphasalazine in an experimental model of rat colitis."	3.68	Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. ( Camerini, R; Caputi, AP; Graziani, P; Squadrito, F; Zingarelli, B, 1993)
"pylori."	2.69	Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. ( Duncan, HD; Green, JR; Pearce, CB; Timmis, L, 2000)
"Mesalamine was associated with a modest reduction in the odds ratio (OR) of CRN (OR = 0."	2.52	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. ( Akbari, M; Moss, AC; OʼConnor, A; Packey, CD, 2015)
"Crohn's disease and ulcerative colitis, together popularly known as inflammatory bowel disease (IBD), are characterized by a number of extraintestinal manifestations."	2.46	Pancreatitis in inflammatory bowel diseases. ( Das, K; Pitchumoni, CS; Rubin, A, 2010)
"ulcerative colitis and Crohn's disease), for both active disease and the control of remission."	2.44	Drug insight: aminosalicylates for the treatment of IBD. ( Munck, LK; Nielsen, OH, 2007)
" Therapeutic success of mesalazine may be optimized by a combination of high dose and low frequency of dosage to improve compliance."	2.43	Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? ( Mulder, CJ; van Bodegraven, AA, 2006)
"Ulcerative colitis (UC) and Crohn's disease (CD), collectively known as inflammatory bowel disease (IBD), afflict an estimated one million Americans and produce symptoms that impair quality of life and ability to function."	2.42	The state of the art in the management of inflammatory bowel disease. ( Hanauer, SB; Present, DH, 2003)
"The role of salicylates in Crohn's disease is limited to the mild activity phase; further data are required to clarify its role in maintenance on remission."	2.41	New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. ( Campieri, M, 2002)
"The main standards of Crohn's disease therapy are presented on the bases of the small bowel Crohn's disease."	2.41	[Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002)
"Since reactive arthritis is induced by specific urogenital or enterogenic bacteriae, and since the gut is implicated in different forms of spondyloarthropathies, especially in IBD, it was clear that the gut could play an important role by permitting exogenous factors to enter the body."	2.39	The role of gut inflammation in the pathogenesis of spondyloarthropathies. ( Cuvelier, C; De Vos, M; Mielants, H; Veys, EM, 1996)
" Differences found in the incidence of side effects among the various disease groups can probably be explained by patient selection, particularly with respect to age, proportion treated for the first time with sulphasalazine, and dosage used."	2.38	Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis. ( Van 'T Hof, MA; Van De Putte, LB; Van Riel, PL; Wijnands, MJ, 1993)
" Sulfasalazine may cause reversible male infertility, but it is entirely safe for use during pregnancy and lactation."	2.37	The safety of sulfasalazine: the gastroenterologists' experience. ( Sachar, DB, 1988)
"The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission."	1.62	COVID-19 in IBD: The experience of a single tertiary IBD center. ( Belluzzi, A; Calabrese, C; Calandrini, L; Decorato, A; Dussias, N; Filippone, E; Gionchetti, P; Laureti, S; Melotti, L; Peruzzi, G; Poggioli, G; Privitera, H; Rizzello, F; Rottoli, M; Salice, M; Scaioli, E; Siniscalchi, A, 2021)
"The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown."	1.56	Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. ( Brenner, EJ; Colombel, JF; Gearry, RB; Kaplan, GG; Kappelman, MD; Kissous-Hunt, M; Lewis, JD; Ng, SC; Rahier, JF; Reinisch, W; Ruemmele, FM; Steinwurz, F; Underwood, FE; Ungaro, RC; Zhang, X, 2020)
"Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs."	1.48	NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. ( Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018)
"Aminosalicylate (5-ASA) is effective treatment for inflammatory bowel diseases (IBDs) but requires continuous maintenance therapy."	1.40	Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. ( Kemp, A; Leong, RW; Selinger, CP, 2014)
"Colitis was induced by administration of 3% DSS in drinking water to mice for 7days followed by 5days of normal drinking water."	1.39	Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice. ( Igaki, K; Sha, T; Tsuchimori, N; Watanabe, T; Yamasaki, M, 2013)
" The present study aimed to investigate the effect of different doses of pioglitazone alone and in combination with sulfasalazine in TNBS (trinitrobenzenesulfonic acid)-induced inflammatory bowel disease (IBD) in rats."	1.39	Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. ( Byrav D S, P; Chakrabarti, A; Khanduja, KL; Medhi, B; Prakash, A; Vaiphei, K, 2013)
"The study showed that green tea alone and in combination with sulfasalazine reduced inflammatory changes induced by tri nitro benzene sulfonic acid in rats."	1.37	Comparative evaluation of different doses of green tea extract alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. ( Byrav, DS; Chakrabarti, A; Khanduja, KL; Medhi, B; Vaiphei, K, 2011)
" Because sulfasalazine presents serious side effects through long-term use at high doses, the aim of the present study was to evaluate the preventative effect of polydextrose on trinitrobenzenesulfonic acid-induced intestinal inflammation and its effects on the intestinal anti-inflammatory activity of sulfasalazine."	1.36	Dietary polydextrose prevents inflammatory bowel disease in trinitrobenzenesulfonic acid model of rat colitis. ( Di Stasi, LC; Fruet, AC; Salem, L; Witaicenis, A, 2010)
"Colitis was induced by a single intracolonic administration of TNBS dissolved in 35% ethanol."	1.35	Effect of different doses of Manuka honey in experimentally induced inflammatory bowel disease in rats. ( Avti, PK; Khanduja, KL; Medhi, B; Pandhi, P; Prakash, A; Saikia, UN, 2008)
"Treatment with thalidomide restored malondialdehyde as well as reduction of myeloperoxidase and tumour necrosis factor-alpha towards normal levels."	1.35	Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. ( Medhi, B; Pandhi, P; Prakash, O; Saikia, UN, 2008)
"The NAT2 gene polymorphism was not associated with susceptibility to IBD in Chinese populations, but the NAT2 slow acetylator genotypes were significantly associated with SP dose-related adverse effects of SASP in the treatment of IBD."	1.34	N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. ( Chen, B; Chen, M; Guo, Q; Hu, Z; Li, J; Xia, B; Ye, M, 2007)
"Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine."	1.31	Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. ( Rane, A; Stjernberg, E; Wadelius, M; Wiholm, BE, 2000)
"Analysis of suspected serious adverse reactions reported to the Committee on Safety of Medicines of the UK in 1991-1998."	1.31	Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. ( Langman, MJ; Ransford, RA, 2002)
"A multiple unit dosage form for oral delivery based on the microencapsulation of anti-inflammatory drugs using different biodegradable polymers, poly(epsilon-caprolactone), polylactic acid and poly(lactic-co-glycolic acid), prepared either by the water-in-oil-in-water (w/o/w) or the solid-in-oil-in-water (s/o/w) solvent evaporation method was developed."	1.31	Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. ( Lamprecht, A; Lehr, CM; Rodero Torres, H; Schäfer, U, 2000)
"An acute respiratory failure occurred 36 hours after from admission due to an obstructive and desquamative necrosis of the tracheobronchial epithelium."	1.31	[Fatal toxic respiratory epitheliolysis. Subacute tracheo-bronchial desquamation in Stevens-Johnson syndrome]. ( Hazouard, E; Machet, L; Martin, L; Maurage, C; Michalak-Provost, S, 2001)
"When arachidonic acid was added to the cell suspension, it significantly stimulated LTB4 synthesis, especially in patients with active disease."	1.29	Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease. ( Baumeister, B; Kosché, E; Schmidt, C; Vetter, H, 1995)
"6-Mercaptopurine has been used with increasing frequency in refractory inflammatory bowel disease; the use of cyclosporine A for this condition is still under investigation."	1.29	Cyclosporine and 6-mercaptopurine in pediatric inflammatory bowel disease. ( La Tulippe Naccarini, DA; Minor, ML, 1994)
"Sulfasalazine was discontinued in all after symptoms of hypersensitivity developed."	1.28	Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. ( Tolia, V, 1992)
"An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease."	1.28	The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. ( Crouch, R; Davis, AE; Patterson, F, 1992)
"Drug treatment with sulfasalazine or 5-aminosalicylic acid improved enteritis score."	1.28	Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. ( Selve, N, 1992)
"5%) had adverse effects that led to discontinuation of therapy in 14 (11."	1.28	Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. ( Levy, M; Rachmilewitz, D; Rahav, G; Zylber-Katz, E, 1990)
"These four patients (two with Crohn's disease and two with nonspecific colitis) were entered into the second phase of the study."	1.28	Does proctosigmoiditis in inflammatory bowel disease presage the imminent onset of symptoms? ( Aiges, H; Daum, F; Kahn, E; Markowitz, J; Rosa, J; Simpser, E, 1989)
" Moreover, 1 drug should be used in appropriate dosage before it is assumed to be inefficient."	1.28	Ankylosing spondylitis. Current drug treatment. ( Gran, JT; Husby, G, 1992)

Research

Studies (199)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Hospital Anxiety and Depression Score-Anxiety, (HADSA) at Week 13

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (9.55)	18.7374
1990's	69 (34.67)	18.2507
2000's	60 (30.15)	29.6817
2010's	37 (18.59)	24.3611
2020's	14 (7.04)	2.80

Authors	Studies
Pellicciari, R	1
Garzon-Aburbeh, A	1
Natalini, B	1
Marinozzi, M	1
Clerici, C	1
Gentili, G	1
Morelli, A	1
Dhaneshwar, SS	3
Gairola, N	2
Kandpal, M	2
Bhatt, L	2
Vadnerkar, G	2
Kadam, SS	2
Rathi, B	1
Abdel-Aziz, H	1
Wadie, W	1
Scherner, O	1
Efferth, T	1
Khayyal, MT	1
Banskota, S	3
Kang, HE	1
Kim, DG	1
Park, SW	1
Jang, H	1
Karmacharya, U	1
Jeong, BS	1
Kim, JA	3
Nam, TG	1
Kadayat, TM	2
Gurung, P	2
Bist, G	2
Thapa Magar, TB	1
Shrestha, A	2
Lee, ES	2
Magar, TBT	1
Lohning, A	1
Kidachi, Y	1
Kamiie, K	1
Sasaki, K	1
Ryoyama, K	1
Yamaguchi, H	1
Jiang, Q	1
Xu, Q	1
Wang, Y	2
Li, P	1
Zhang, Y	1
Sun, J	1
Zhang, T	1
He, Z	1
Ungaro, RC	3
Brenner, EJ	3
Agrawal, M	1
Zhang, X	5
Kappelman, MD	3
Colombel, JF	4
Xia, P	1
Hou, T	1
Ma, M	1
Li, S	1
Jin, H	1
Luo, X	1
Li, J	2
Geng, F	1
Li, B	1
Broekaert, IJ	3
Klein, A	3
Windschall, D	3
Rogalski, B	3
Weller-Heinemann, F	3
Oommen, P	3
Küster, M	3
Foeldvari, I	3
Minden, K	3
Hospach, A	3
Hufnagel, M	3
Berger, T	3
Geikowski, T	3
Quietzsch, J	3
Horneff, G	3
Momen Majumder, MS	1
Haq, SA	1
Rasker, JJ	1
Jeong, S	1
Lee, H	1
Kim, S	1
Ju, S	1
Kim, W	1
Cho, H	2
Kim, HY	1
Heo, G	1
Im, E	1
Yoo, JW	1
Yoon, IS	1
Jung, Y	1
Hammami, MB	1
Mahadevan, U	1
Yousefi-Ahmadipour, A	1
Ebrahimi-Barough, S	1
Niknia, S	1
Allahverdi, A	1
Mirzahosseini-Pourranjbar, A	1
Tashakori, M	1
Khajouee Ravari, S	1
Asadi, F	1
Heidari Barchi Nezhad, R	1
Lotfibakhshaiesh, N	1
Mirzaei, MR	1
Gearry, RB	1
Kaplan, GG	2
Kissous-Hunt, M	1
Lewis, JD	2
Ng, SC	1
Rahier, JF	1
Reinisch, W	1
Ruemmele, FM	2
Steinwurz, F	1
Underwood, FE	1
Pigneur, B	1
Focht, G	1
Turner, D	1
Jeličić, ML	1
Brusač, E	1
Klarić, DA	1
Nigović, B	1
Turk, N	1
Mornar, A	1
Rizzello, F	1
Calabrese, C	1
Salice, M	1
Calandrini, L	1
Privitera, H	1
Melotti, L	1
Peruzzi, G	1
Dussias, N	1
Belluzzi, A	1
Scaioli, E	1
Decorato, A	1
Siniscalchi, A	1
Filippone, E	1
Laureti, S	1
Rottoli, M	1
Poggioli, G	1
Gionchetti, P	1
Roy, S	1
Sheikh, SZ	1
Furey, TS	1
Murugan, R	1
Saravanan, S	1
Parimelazhagan, T	1
McCreary, DJ	1
Millman, G	1
Niknahad, H	1
Heidari, R	1
Mohammadzadeh, R	1
Ommati, MM	1
Khodaei, F	1
Azarpira, N	1
Abdoli, N	1
Zarei, M	1
Asadi, B	1
Rasti, M	1
Shirazi Yeganeh, B	1
Taheri, V	1
Saeedi, A	1
Najibi, A	1
Valcheva-Kuzmanova, S	1
Kuzmanov, A	1
Kuzmanova, V	1
Tzaneva, M	1
Kakuta, Y	1
Kawai, Y	1
Okamoto, D	1
Takagawa, T	1
Ikeya, K	1
Sakuraba, H	1
Nishida, A	1
Nakagawa, S	1
Miura, M	1
Toyonaga, T	1
Onodera, K	1
Shinozaki, M	1
Ishiguro, Y	1
Mizuno, S	1
Takahara, M	1
Yanai, S	1
Hokari, R	1
Nakagawa, T	1
Araki, H	1
Motoya, S	1
Naito, T	1
Moroi, R	1
Shiga, H	1
Endo, K	1
Kobayashi, T	1
Naganuma, M	1
Hiraoka, S	1
Matsumoto, T	2
Nakamura, S	1
Nakase, H	1
Hisamatsu, T	1
Sasaki, M	1
Hanai, H	1
Andoh, A	1
Nagasaki, M	1
Kinouchi, Y	1
Shimosegawa, T	1
Masamune, A	1
Suzuki, Y	1
Felice, C	1
Pugliese, D	1
Papparella, LG	1
Pizzolante, F	1
Onori, E	1
Gasbarrini, A	1
Rapaccini, GL	1
Guidi, L	1
Armuzzi, A	1
Liu, X	1
Yu, X	1
Xu, X	1
Ghattamaneni, NKR	1
Panchal, SK	1
Brown, L	1
Suneela, D	1
Gaurav, V	1
Himanshu, R	1
Byrav D S, P	1
Medhi, B	5
Prakash, A	2
Chakrabarti, A	2
Vaiphei, K	2
Khanduja, KL	3
Selinger, CP	1
Kemp, A	1
Leong, RW	1
Huang, VW	1
Habal, FM	1
Zhou, Y	1
Ruan, Z	1
Zhou, X	1
Huang, X	1
Li, H	1
Wang, L	1
Zhang, C	1
Liu, S	1
Deng, Z	1
Wu, G	1
Yin, Y	1
Silva-Fernández, L	1
Pérez-Vicente, S	1
Martín-Martínez, MA	1
López-González, R	1
OʼConnor, A	1
Packey, CD	1
Akbari, M	1
Moss, AC	1
Quaglio, AE	1
Castilho, AC	1
Di Stasi, LC	2
Maxwell, EC	1
Grossman, AB	1
Kandula, M	1
Sunil Kumar, KB	1
Palanichamy, S	1
Rampal, A	1
Prakash, O	2
Saikia, UN	3
Pandhi, P	3
Brar, H	1
Einarson, A	1
Avti, PK	1
Marteau, P	1
Harris, A	1
Feller, ER	1
Shah, SA	2
Saha, S	1
Esposti, SD	1
Seow, CH	1
de Silva, S	1
Devlin, SM	1
Ghosh, S	1
Panaccione, R	1
Rodríguez-Reyna, TS	1
Martínez-Reyes, C	1
Yamamoto-Furusho, JK	1
He, C	1
Zhang, SL	1
Hu, CJ	1
Tong, DW	1
Li, YZ	1
Wilson, DC	1
Thomas, AG	1
Croft, NM	1
Newby, E	1
Akobeng, AK	1
Sawczenko, A	1
Fell, JM	1
Murphy, MS	1
Beattie, RM	1
Sandhu, BK	1
Mitton, SG	1
Casson, D	1
Elawad, M	1
Heuschkel, R	1
Jenkins, H	1
Johnson, T	1
Macdonald, S	1
Murch, SH	1
Pitchumoni, CS	1
Rubin, A	1
Das, K	1
Smith, MA	1
Marinaki, AM	1
Sanderson, JD	1
Azevedo, LF	1
Magro, F	1
Portela, F	1
Lago, P	1
Deus, J	1
Cotter, J	1
Cremers, I	1
Vieira, A	1
Peixe, P	1
Caldeira, P	1
Lopes, H	1
Gonçalves, R	1
Reis, J	1
Cravo, M	1
Barros, L	1
Ministro, P	1
Lurdes, M	1
Duarte, A	1
Campos, M	1
Carvalho, L	1
Costa-Pereira, A	1
Nguyen, TM	1
Le Gall, C	1
Lachaux, A	1
Boulieu, R	1
Dijkstra, G	1
Derijks, LJ	1
Houwert, GJ	1
Wolf, H	1
van Bodegraven, AA	3
Byrav, DS	1
Witaicenis, A	1
Fruet, AC	1
Salem, L	1
Linares, V	1
Alonso, V	1
Domingo, JL	1
Oustamanolakis, P	1
Koutroubakis, IE	1
Messaritakis, I	1
Malliaraki, N	1
Sfiridaki, A	1
Kouroumalis, EA	1
Castro Villegas, Mdel C	1
Escudero Contreras, A	1
Miranda García, MD	1
Collantes Estévez, E	1
Sha, T	1
Igaki, K	1
Yamasaki, M	1
Watanabe, T	1
Tsuchimori, N	1
Wolf, JM	1
Lashner, BA	1
Ransford, RA	1
Langman, MJ	1
Travis, SP	2
Jergens, AE	2
Alstead, EM	1
Nelson-Piercy, C	1
Nagy, F	1
Edmond, LM	1
Hopkins, MJ	1
Magee, EA	1
Cummings, JH	1
Hanauer, SB	4
Present, DH	2
Ohtani, T	1
Hiroi, A	1
Sakurane, M	1
Furukawa, F	1
Oshitani, N	1
Hato, F	1
Kitagawa, S	1
Watanabe, K	1
Fujiwara, Y	1
Higuchi, K	1
Arakawa, T	1
Singh, VP	1
Patil, CS	1
Jain, NK	1
Singh, A	1
Kulkarni, SK	1
D'Haens, G	1
Munk, EM	1
Pedersen, L	1
Floyd, A	1
Nørgård, B	2
Rasmussen, HH	1
Sørensen, HT	2
Meyer, AM	1
Ramzan, NN	1
Loftus, EV	2
Heigh, RI	1
Leighton, JA	1
Hindorf, U	1
Lyrenäs, E	1
Nilsson, A	1
Schmiegelow, K	1
Tulassay, Z	1
Sauk, J	1
Kane, S	1
Joshi, R	1
Kumar, S	1
Unnikrishnan, M	1
Mukherjee, T	1
Liu, P	1
Yang, J	1
Luo, QL	1
Yu, ZY	1
Bergman, R	1
Parkes, M	1
Mulder, CJ	1
Braun, J	1
Sieper, J	1
Terdiman, JP	1
Steinbuch, M	1
Blumentals, WA	1
Ullman, TA	1
Rubin, DT	1
Jess, T	1
Velayos, FS	1
Winther, KV	1
Tremaine, WJ	1
Zinsmeister, AR	1
Scott Harmsen, W	1
Langholz, E	1
Binder, V	1
Munkholm, P	1
Sandborn, WJ	2
Nielsen, OH	1
Munck, LK	1
Chen, M	1
Xia, B	1
Chen, B	1
Guo, Q	1
Ye, M	1
Hu, Z	1
Cozzi, F	1
Podswiadek, M	1
Cardinale, G	1
Oliviero, F	1
Dani, L	1
Sfriso, P	1
Punzi, L	1
Heetun, ZS	1
Byrnes, C	1
Neary, P	1
O'Morain, C	1
Peh, KH	1
Wan, BC	1
Assem, ES	1
Pearce, FL	1
Moffatt, DC	1
Bernstein, CN	1
Vroom, F	1
van Roon, EN	1
van den Berg, PB	1
Brouwers, JR	1
de Jong-van den Berg, LT	1
Sheldon, P	1
Pell, P	1
Peppercorn, MA	2
Hirschfeld, S	1
Clearfield, HR	1
Varela, E	1
Mäki-Ikola, O	1
Nissilä, M	1
Lehtinen, K	1
Leirisalo-Repo, M	1
Toivanen, P	1
Granfors, K	1
Zingarelli, B	1
Squadrito, F	1
Graziani, P	1
Camerini, R	1
Caputi, AP	1
La Tulippe Naccarini, DA	1
Minor, ML	1
Jewell, DP	1
Hessemer, CA	1
Schinagl, EF	1
Wijnands, MJ	1
Van 'T Hof, MA	1
Van De Putte, LB	1
Van Riel, PL	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834]		472 participants (Actual)	Observational	2020-05-15	Active, not recruiting
The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients[NCT03145896]		40 participants (Anticipated)	Interventional	2017-06-01	Not yet recruiting
Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163]		26 participants (Actual)	Interventional	2007-10-31	Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available)
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982]	Phase 2	0 participants (Actual)	Interventional	2007-08-07	Withdrawn
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease[NCT00152620]		40 participants	Interventional	2004-06-30	Terminated (stopped due to study completed)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks

Hospital Anxiety and Depression Score-Depression (HADSD)

Intervention	score on a scale (Median)
UC Patients Given Gut-focussed Hpynotherapy	7
UC Patients Given Control Educational Sessions	10

Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks

Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 13

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	1.5
UC Patients Given Control Educational Sessions	4

IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks

Perceived Stress Questionnaire-Recent (PSQ-R)

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	195
UC Patients Given Control Educational Sessions	192

Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks

Relapse at 1 Year

Intervention	units on a scale (Median)
UC Patients Given Gut-focussed Hypnotherapy	0.3
UC Patients Given Control Educational Sessions	0.4

The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year

Article	Year
Men With Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer. The American journal of gastroenterology, 2020, Volume: 115, Issue:4 Topics: Depression; Gastrointestinal Agents; Humans; Infertility, Male; Inflammatory Bowel Diseases; Male; M	2020
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases. Expert review of clinical immunology, 2018, Volume: 14, Issue:9 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Evidence-Based	2018
From conception to delivery: managing the pregnant inflammatory bowel disease patient. World journal of gastroenterology, 2014, Apr-07, Volume: 20, Issue:13 Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Anti-Bacterial Agents; Azathioprine; Biological Produc	2014
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease. World journal of gastroenterology, 2014, Apr-07, Volume: 20, Issue:13 Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colon; Fatty Acids, Omega-3; He	2014
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. Inflammatory bowel diseases, 2015, Volume: 21, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Inflammatory Bowel Diseases;	2015
Advances in Pediatric Inflammatory Bowel Disease. Adolescent medicine: state of the art reviews, 2016,Spring, Volume: 27, Issue:1 Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal, Huma	2016
Reproductive issues in inflammatory bowel disease. Medicine and health, Rhode Island, 2009, Volume: 92, Issue:4 Topics: Adaptation, Psychological; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathio	2009
Rheumatic manifestations of inflammatory bowel disease. World journal of gastroenterology, 2009, Nov-28, Volume: 15, Issue:44 Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cadherins; Cytokines; Gastroenter	2009
Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 2010, Volume: 50 Suppl 1 Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Child;	2010
Pancreatitis in inflammatory bowel diseases. Journal of clinical gastroenterology, 2010, Volume: 44, Issue:4 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Dis	2010
Pharmacogenomics in the treatment of inflammatory bowel disease. Pharmacogenomics, 2010, Volume: 11, Issue:3 Topics: Adrenal Cortex Hormones; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transpo	2010
Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert opinion on drug safety, 2011, Volume: 10, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Lipid Peroxid	2011
[How to optimize the antiTNF alpha therapy in spondylitis?]. Reumatologia clinica, 2012, Volume: 8 Suppl 1 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheu	2012
Inflammatory bowel disease: sorting out the treatment options. Cleveland Clinic journal of medicine, 2002, Volume: 69, Issue:8 Topics: Anti-Inflammatory Agents; Azathioprine; Clinical Trials as Topic; Cyclosporine; Fish Oils; Humans; I	2002
Feline inflammatory bowel disease--current perspectives on etiopathogenesis and therapy. Journal of feline medicine and surgery, 2002, Volume: 4, Issue:3 Topics: Adrenal Cortex Hormones; Animal Nutritional Physiological Phenomena; Animals; Azathioprine; Cat Dise	2002
[Conservative therapy of inflammatory bowel diseases]. Orvosi hetilap, 2002, Dec-15, Volume: 143, Issue:50 Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro	2002
The state of the art in the management of inflammatory bowel disease. Reviews in gastroenterological disorders, 2003,Spring, Volume: 3, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Dos	2003
[Pharmacogenetics of inflammatory bowel disease]. Orvosi hetilap, 2005, May-22, Volume: 146, Issue:21 Topics: Aminosalicylic Acids; Animals; Antibodies, Monoclonal; Azathioprine; Glucocorticoids; Humans; Immuno	2005
The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:11 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; B	2005
Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7 Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida	2006
Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7 Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida	2006
Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7 Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida	2006
Systematic review: the use of mesalazine in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 2006, Apr-01, Volume: 23, Issue:7 Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida	2006
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World journal of gastroenterology, 2006, Oct-14, Volume: 12, Issue:38 Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Colonic Neoplasms; Humans; Inflammatory Bow	2006
Drug insight: aminosalicylates for the treatment of IBD. Nature clinical practice. Gastroenterology & hepatology, 2007, Volume: 4, Issue:3 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative;	2007
Review article: Reproduction in the patient with inflammatory bowel disease. Alimentary pharmacology & therapeutics, 2007, Aug-15, Volume: 26, Issue:4 Topics: Adult; Azathioprine; Breast Feeding; Female; Fertility; Humans; Immunosuppressive Agents; Inflammato	2007
Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Best practice & research. Clinical gastroenterology, 2007, Volume: 21, Issue:5 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antidiarrheals; Fe	2007
Inflammatory bowel disease therapy: an update. Comprehensive therapy, 1995, Volume: 21, Issue:6 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Humans; Immunologic Factors; Inflammatory Bowel Dise	1995
Pharmacologic therapy for inflammatory bowel disease. American family physician, 1995, Volume: 51, Issue:8 Topics: Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Anti-	1995
Salicylates for inflammatory bowel disease. Bailliere's clinical gastroenterology, 1994, Volume: 8, Issue:2 Topics: Aminosalicylic Acids; Controlled Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Mesa	1994
Rheumatoid arthritis: a risk factor for sulphasalazine toxicity? A meta-analysis. British journal of rheumatology, 1993, Volume: 32, Issue:4 Topics: Arthritis, Rheumatoid; Humans; Inflammatory Bowel Diseases; Risk Factors; Spinal Diseases; Sulfasala	1993
[New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease]. Harefuah, 1993, Feb-15, Volume: 124, Issue:4 Topics: Aminosalicylic Acids; Chronic Disease; Humans; Inflammatory Bowel Diseases; Sulfasalazine	1993
Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:4 Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazine	1993
[Emergency drug therapy of non-specific inflammatory bowel diseases--progress on diagnosis and therapy]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1995, Nov-10, Volume: 84, Issue:11 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Animals; Anti-Inflammatory Agents; Drug Combin	1995
[Significance of intestinal inflammation in the pathogenesis of spondylarthropathies]. Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1996, Volume: 58, Issue:2 Topics: Animals; Animals, Genetically Modified; Chronic Disease; Endoscopy, Gastrointestinal; HLA-B27 Antige	1996
The role of gut inflammation in the pathogenesis of spondyloarthropathies. Acta clinica Belgica, 1996, Volume: 51, Issue:5 Topics: Anti-Inflammatory Agents; Arthritis, Reactive; Cell Membrane Permeability; Colonoscopy; HLA-B27 Anti	1996
Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease. Pharmacology & toxicology, 1997, Volume: 81 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Humans; Inflammatory Bowel Dis	1997
The treatment of inflammatory bowel disease in children. Clinical pediatrics, 1998, Volume: 37, Issue:7 Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Crohn Disease; Fe	1998
[Present states of development in new drugs and treatment of inflammatory bowel disease]. Nihon rinsho. Japanese journal of clinical medicine, 1999, Volume: 57, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Glucocorticoids; Humans; I	1999
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores]. Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:10 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulc	1999
Comparative tolerability of treatments for inflammatory bowel disease. Drug safety, 2000, Volume: 23, Issue:5 Topics: Adrenal Cortex Hormones; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Female; Gas	2000
Inflammatory bowel disease and pregnancy. Inflammatory bowel diseases, 2001, Volume: 7, Issue:2 Topics: Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Disease; Female; Fert	2001
Prostaglandin biology in inflammatory bowel disease. Gastroenterology clinics of North America, 2001, Volume: 30, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena	2001
[Is the lung a target organ in inflammatory bowel disease?]. Recenti progressi in medicina, 2001, Volume: 92, Issue:12 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bronchial Diseases	2001
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut, 2002, Volume: 50 Suppl 3 Topics: Acute Disease; Aspirin; Beclomethasone; Budesonide; Colitis, Ulcerative; Crohn Disease; Drug Therapy	2002
Sulphasalazine and lung toxicity. The European respiratory journal, 2002, Volume: 19, Issue:4 Topics: Antirheumatic Agents; Colitis, Ulcerative; Female; Humans; Inflammatory Bowel Diseases; Lung Disease	2002
Inflammatory bowel disease and pregnancy. International journal of colorectal disease, 2002, Volume: 17, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Colectomy; Delivery, Obstetric; Episiotomy; Female; Humans; Immunosu	2002
Sulfasalazine-induced fulminant hepatic failure. Journal of clinical gastroenterology, 1992, Volume: 14, Issue:2 Topics: Adult; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Female; Hepatic Encephalopathy;	1992
Sulfasalazine. Multiplicity of action. Digestive diseases and sciences, 1992, Volume: 37, Issue:6 Topics: Aminosalicylic Acids; Animals; Free Radical Scavengers; Humans; Hydroxyeicosatetraenoic Acids; Infla	1992
Outpatient management of inflammatory bowel disease. Let's keep it as simple as possible. Postgraduate medicine, 1992, Nov-01, Volume: 92, Issue:6 Topics: Abdominal Pain; Adrenal Cortex Hormones; Ambulatory Care; Aminosalicylic Acids; Anus Diseases; Diarr	1992
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents and actions, 1992, Volume: Spec No Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do	1992
Chronic inflammatory bowel disease. Archives of disease in childhood, 1991, Volume: 66, Issue:6 Topics: Child, Preschool; Food Hypersensitivity; Food, Formulated; Growth Disorders; Humans; Infant; Inflamm	1991
[New salicylic acid derivatives in the treatment of inflammatory intestinal diseases]. Orvosi hetilap, 1991, Jun-16, Volume: 132, Issue:24 Topics: Aminosalicylic Acids; Chronic Disease; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazin	1991
[Experiences with phase III studies in the area of gastroenterology]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1991, Volume: 97 Topics: Aminosalicylic Acids; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Mesalamine; Sul	1991
Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 172 Topics: Arachidonic Acids; Chemotaxis; Eicosanoids; Humans; Inflammatory Bowel Diseases; Leukotriene B4; Sul	1990
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomen. Journal of clinical gastroenterology, 1990, Volume: 12, Issue:4 Topics: Abdomen, Acute; Adrenocorticotropic Hormone; Adult; Aminosalicylic Acids; Cortisone; Diagnosis, Diff	1990
Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. The Quarterly journal of medicine, 1990, Volume: 75, Issue:278 Topics: Aminosalicylic Acids; Humans; Inflammatory Bowel Diseases; Sulfasalazine	1990
Inflammatory bowel disease revisited: newer drugs. Scandinavian journal of gastroenterology. Supplement, 1990, Volume: 175 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Humans; Immunosuppressive Agents; Inflammatory Bowel	1990
Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. Journal of pediatric gastroenterology and nutrition, 1989, Volume: 8, Issue:3 Topics: Administration, Oral; Adolescent; Aminosalicylic Acids; Chronic Disease; Colitis; Drug Tolerance; Fe	1989
Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 1989, Volume: 8, Issue:4 Topics: Adolescent; Chemical and Drug Induced Liver Injury; Female; Humans; Inflammatory Bowel Diseases; Sul	1989
Inflammatory bowel disease. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1989, Jul-15, Volume: 141, Issue:2 Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Delayed-Action Preparations; Dr	1989
Pregnancy and inflammatory bowel disease. The Western journal of medicine, 1989, Volume: 151, Issue:2 Topics: Adrenal Cortex Hormones; Female; Humans; Ileostomy; Inflammatory Bowel Diseases; Pregnancy; Pregnanc	1989
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease. Danish medical bulletin, 1989, Volume: 36, Issue:4 Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Leuko	1989
Update on the aminosalicylates: a promise fulfilled. Gastroenterology, 1988, Volume: 95, Issue:6 Topics: Aminosalicylic Acids; Canada; Europe; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalazine	1988
The safety of sulfasalazine: the gastroenterologists' experience. The Journal of rheumatology. Supplement, 1988, Volume: 16 Topics: Drug Hypersensitivity; Humans; Inflammatory Bowel Diseases; Sulfasalazine	1988
Treatment of the seronegative spondyloarthropathies with sulfasalazine. The Journal of rheumatology. Supplement, 1988, Volume: 16 Topics: Adolescent; Adult; Arthritis; Female; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Spondy	1988

Article	Year
Brush-border-enzyme-mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid. Journal of medicinal chemistry, 1993, Dec-24, Volume: 36, Issue:26 Topics: Amino Acids; Aminopeptidases; Aminosalicylic Acids; Animals; Carboxypeptidases; Colon; Colostomy; Fe	1993
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease. Bioorganic & medicinal chemistry letters, 2007, Apr-01, Volume: 17, Issue:7 Topics: Animals; Chemistry, Pharmaceutical; Colon; Drug Delivery Systems; Drug Design; Hydrochloric Acid; In	2007
Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease. European journal of medicinal chemistry, 2009, Volume: 44, Issue:10 Topics: Aminosalicylic Acids; Animals; Arthritis; Colitis; Colon; Female; Inflammatory Bowel Diseases; Male;	2009
Bacteria-Derived Compatible Solutes Ectoine and 5α-Hydroxyectoine Act as Intestinal Barrier Stabilizers to Ameliorate Experimental Inflammatory Bowel Disease. Journal of natural products, 2015, Jun-26, Volume: 78, Issue:6 Topics: Amino Acids, Diamino; Animals; Bacteria; Colitis; Colon; Egypt; Glutathione; Humans; Inflammatory Bo	2015
In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease. Bioorganic & medicinal chemistry letters, 2016, 10-01, Volume: 26, Issue:19 Topics: Humans; In Vitro Techniques; Inflammatory Bowel Diseases; Pyridines	2016
Discovery and structure-activity relationship studies of 2-benzylidene-2,3-dihydro-1H-inden-1-one and benzofuran-3(2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease. European journal of medicinal chemistry, 2017, Sep-08, Volume: 137 Topics: Animals; Benzofurans; Colitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discov	2017
Synthesis and biological evaluation of pyridine-linked indanone derivatives: Potential agents for inflammatory bowel disease. Bioorganic & medicinal chemistry letters, 2018, 08-01, Volume: 28, Issue:14 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion; Colitis; Dise	2018
6-(methylsulfinyl)hexyl isothiocyanate (6-MITC) from Wasabia japonica alleviates inflammatory bowel disease (IBD) by potential inhibition of glycogen synthase kinase 3 beta (GSK-3β). European journal of medicinal chemistry, 2021, Apr-15, Volume: 216 Topics: Animals; Anti-Inflammatory Agents; Cell Line; Dextran Sulfate; Down-Regulation; Female; Glycogen Syn	2021
Modulation of Naturally Occurring Linear Dipeptide Chirality to Reduce the Affinity for Oligopeptide Transporter 1 and Increase Intestinal Stability for an Enhanced Colon-Targeting Effect in the Treatment of Inflammatory Bowel Disease: An Application of Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6 Topics: Colon; Dipeptides; Humans; Inflammatory Bowel Diseases; Peptide Transporter 1; Serine; Symporters	2022
Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry. Gastroenterology, 2022, Volume: 162, Issue:1 Topics: Adrenal Cortex Hormones; COVID-19; Humans; Inflammatory Bowel Diseases; Mesalamine; Registries; SARS	2022
Konjac oligosaccharides attenuate DSS-induced ulcerative colitis in mice: mechanistic insights. Food & function, 2022, May-23, Volume: 13, Issue:10 Topics: Amorphophallus; Animals; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Mo	2022
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Development of Inflammatory Bowel Disease in Children With Juvenile Idiopathic Arthritis Treated With Biologics. Journal of pediatric gastroenterology and nutrition, 2023, 02-01, Volume: 76, Issue:2 Topics: Antirheumatic Agents; Arthritis, Juvenile; Biological Products; Child; Colitis, Ulcerative; Crohn Di	2023
Tofacitinib for the treatment of inflammatory bowel disease-associated arthritis: two case reports. Journal of medical case reports, 2023, Mar-01, Volume: 17, Issue:1 Topics: Adult; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory Bowel	2023
5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity. Molecular pharmaceutics, 2020, 01-06, Volume: 17, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Chromatography, Liquid; Colitis;	2020
Therapeutic effects of combination of platelet lysate and sulfasalazine administration in TNBS-induced colitis in rat. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 125 Topics: Animals; Apoptosis; Blood Platelets; Colitis; Combined Modality Therapy; Cytokines; Disease Models,	2020
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology, 2020, Volume: 159, Issue:2 Topics: Adrenal Cortex Hormones; Adult; Aged; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19	2020
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021, Volume: 19, Issue:2 Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co	2021
A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn's disease and ulcerative colitis. Scientific reports, 2020, 11-30, Volume: 10, Issue:1 Topics: Chromatography; Colitis, Ulcerative; Crohn Disease; Drug Combinations; Folic Acid; Humans; Inflammat	2020
COVID-19 in IBD: The experience of a single tertiary IBD center. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021, Volume: 53, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biological Products;	2021
A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD. Scientific reports, 2021, 08-13, Volume: 11, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P	2021
Study of intestinal anti-inflammatory activity of Phoenix loureiroi Kunth (Arecaceae) fruit. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 93 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arecaceae; Colitis; Fruit; India; Inflammatory Bowe	2017
Paediatric inflammatory bowel disease: a presenting lesion. Archives of disease in childhood. Education and practice edition, 2018, Volume: 103, Issue:4 Topics: Administration, Oral; Adolescent; Diagnosis, Differential; Drug Therapy, Combination; Erythema Nodos	2018
Sulfasalazine induces mitochondrial dysfunction and renal injury. Renal failure, 2017, Volume: 39, Issue:1 Topics: Acute Kidney Injury; Administration, Oral; Animals; Antioxidants; Arthritis, Rheumatoid; Biomarkers;	2017
Aronia melanocarpa fruit juice ameliorates the symptoms of inflammatory bowel disease in TNBS-induced colitis in rats. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2018, Volume: 113 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Colitis; Disease Models, Animal; Fruit and Vegetabl	2018
NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. Journal of gastroenterology, 2018, Volume: 53, Issue:9 Topics: Alopecia; Antibodies, Monoclonal; Azathioprine; Biomarkers, Pharmacological; Genetic Predisposition	2018
The protective effects of Poria cocos-derived polysaccharide CMP33 against IBD in mice and its molecular mechanism. Food & function, 2018, Nov-14, Volume: 9, Issue:11 Topics: Animals; Chromatography, High Pressure Liquid; Colon; Cytokines; Disease Models, Animal; Dose-Respon	2018
An improved rat model for chronic inflammatory bowel disease. Pharmacological reports : PR, 2019, Volume: 71, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Chronic Disease; Dextran Sulfate; Disease Models, Animal; Gastroi	2019
Design and development of novel azo prodrugs using various permutations and combinations of 5- and 4-aminosalicylic acids for inflammatory bowel disease: a colon-targeted approach. Inflammation & allergy drug targets, 2013, Volume: 12, Issue:5 Topics: Aminosalicylic Acid; Animals; Azo Compounds; Colitis; Colon; Drug Design; Female; Humans; Inflammato	2013
Comparative evaluation of different doses of PPAR-γ agonist alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. Pharmacological reports : PR, 2013, Volume: 65, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Drug Therapy, Co	2013
Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:3 Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Australia; Female; Follo	2014
A diet with lactosucrose supplementation ameliorates trinitrobenzene sulfonic acid-induced colitis in rats. Food & function, 2015, Volume: 6, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colon; Disease Models, Animal; Female; Ga	2015
Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain. Seminars in arthritis and rheumatism, 2015, Volume: 44, Issue:6 Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cohort Studies; Cyclophosphamide; Cyclospo	2015
Experimental evidence of heparanase, Hsp70 and NF-κB gene expression on the response of anti-inflammatory drugs in TNBS-induced colonic inflammation. Life sciences, 2015, Nov-15, Volume: 141 Topics: Animals; Anti-Inflammatory Agents; Azathioprine; Biomarkers; Colitis; Colon; Cytokines; Gene Express	2015
Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases. International immunopharmacology, 2016, Volume: 40 Topics: Aminosalicylic Acids; Animals; Caprylates; Colitis; Colon; Dextran Sulfate; Drug Discovery; Drug Eva	2016
Effect of different doses of thalidomide in experimentally induced inflammatory bowel disease in rats. Basic & clinical pharmacology & toxicology, 2008, Volume: 103, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Models, Animal; Femal	2008
Effects and treatment of inflammatory bowel disease during pregnancy. Canadian family physician Medecin de famille canadien, 2008, Volume: 54, Issue:7 Topics: Abnormalities, Drug-Induced; Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Anti-Infective Ag	2008
Effect of different doses of Manuka honey in experimentally induced inflammatory bowel disease in rats. Phytotherapy research : PTR, 2008, Volume: 22, Issue:11 Topics: Analysis of Variance; Animals; Antioxidants; Colitis; Colon; Disease Models, Animal; Glutathione; Ho	2008
IBD and pregnancy. Inflammatory bowel diseases, 2008, Volume: 14 Suppl 2 Topics: Adult; Fecal Incontinence; Female; Gastrointestinal Agents; Humans; Infertility, Male; Inflammatory	2008
Medical therapy of IBD in 2009. Medicine and health, Rhode Island, 2009, Volume: 92, Issue:3 Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; C	2009
Managing the risks of IBD therapy. Current gastroenterology reports, 2009, Volume: 11, Issue:6 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Glucocorticoids; Humans; Im	2009
Higher levels of CCL20 expression on peripheral blood mononuclear cells of chinese patients with inflammatory bowel disease. Immunological investigations, 2010, Volume: 39, Issue:1 Topics: Adult; Aged; Biomarkers; Biomarkers, Pharmacological; C-Reactive Protein; Chemokine CCL20; China; Di	2010
Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. Pharmacoepidemiology and drug safety, 2010, Volume: 19, Issue:5 Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Female; Gastro	2010
High thiopurine metabolite concentrations associated with lymphopenia in inflammatory bowel disease (IBD) pediatric patients receiving aminosalicylates combined with azathioprine. International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:4 Topics: Adolescent; Aminosalicylic Acids; Azathioprine; Biotransformation; Child; Child, Preschool; Drug The	2010
[Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. II. Special situations and organisation of medical care]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Adult; Female; Humans; Ileostomy; Infertility, Female; Inflammatory Bowel Diseases; Male; Methotrexa	2010
Comparative evaluation of different doses of green tea extract alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats. Digestive diseases and sciences, 2011, Volume: 56, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Camellia sinensis; Dose-Response Relationship, Dru	2011
Dietary polydextrose prevents inflammatory bowel disease in trinitrobenzenesulfonic acid model of rat colitis. Journal of medicinal food, 2010, Volume: 13, Issue:6 Topics: Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colon; Drug Interac	2010
Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. European journal of gastroenterology & hepatology, 2011, Volume: 23, Issue:3 Topics: Adolescent; Adult; Aged; Anemia; Anti-Inflammatory Agents; Antimicrobial Cationic Peptides; Azathiop	2011
Effect of combination of thalidomide and sulfasalazine in experimentally induced inflammatory bowel disease in rats. Indian journal of experimental biology, 2011, Volume: 49, Issue:9 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Disease Models, Animal; Drug Therapy, Combi	2011
Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice. International immunopharmacology, 2013, Volume: 15, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antibodies; Colitis; Cytokines; Dextran Sulfate; Disease Models,	2013
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut, 2002, Volume: 51, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Chemical and Drug Induced Liver Inju	2002
Which 5-ASA? Gut, 2002, Volume: 51, Issue:4 Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Enema; Humans; Inflammatory Bowel Diseases	2002
Inflammatory bowel disease in pregnancy. Gut, 2003, Volume: 52, Issue:2 Topics: Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Infertility,	2003
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflammatory bowel diseases, 2003, Volume: 9, Issue:1 Topics: Amino Acids; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Desul	2003
Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by salazosulfapyridine. The British journal of dermatology, 2003, Volume: 148, Issue:5 Topics: Acetylation; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Case-Con	2003
How safe are the safest IBD drugs? Gastroenterology, 2003, Volume: 124, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Gastrointestinal A	2003
Distinct elevation of levels of anti-Caenorhabditis elegans antibody in sera of patients with inflammatory bowel disease. Clinical and diagnostic laboratory immunology, 2003, Volume: 10, Issue:5 Topics: Adult; Aged; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Caen	2003
Effect of nimesulide on acetic acid- and leukotriene-induced inflammatory bowel disease in rats. Prostaglandins & other lipid mediators, 2003, Volume: 71, Issue:3-4 Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colon; Cyclooxygenase Inhibitors; Inf	2003
Mesalazine is safe for the treatment of IBD. Gut, 2004, Volume: 53, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Mesalamine; Sulfasalaz	2004
Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study. The American journal of gastroenterology, 2004, Volume: 99, Issue:5 Topics: Acute Disease; Adult; Age Distribution; Aged; Aminosalicylic Acids; Case-Control Studies; Confidence	2004
The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. Journal of clinical gastroenterology, 2004, Volume: 38, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Campylobacter jejuni; Clost	2004
Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scandinavian journal of gastroenterology, 2004, Volume: 39, Issue:11 Topics: Adolescent; Adult; Azathioprine; Drug Monitoring; Erythrocytes; Female; Genotype; Guanine Nucleotide	2004
[Chronic inflammatory bowel diseases. Update on evidence-based therapy]. MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17 Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ant	2005
Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity. Free radical research, 2005, Volume: 39, Issue:11 Topics: Aminosalicylic Acids; Anions; Antioxidants; Electrons; Free Radical Scavengers; Free Radicals; Gluta	2005
[Studies on peripheral blood & pathological index in inflammatory bowel disease of rats with clyster No. 1]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2005, Volume: 30, Issue:21 Topics: Animals; Colon; Drug Combinations; Drugs, Chinese Herbal; Enema; Hemoglobins; Inflammatory Bowel Dis	2005
[Spondylarthritides]. Zeitschrift fur Rheumatologie, 2006, Volume: 65, Issue:7 Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Mono	2006
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflammatory bowel diseases, 2007, Volume: 13, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colorectal Neoplasms; Female; H	2007
Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. The American journal of gastroenterology, 2007, Volume: 102, Issue:4 Topics: Adult; Case-Control Studies; Colonoscopy; Colorectal Neoplasms; Denmark; Female; Gastrointestinal Ag	2007
N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2007, Volume: 21, Issue:3 Topics: Acetylation; Acetyltransferases; Adolescent; Adult; Aged; Alleles; Anti-Inflammatory Agents, Non-Ste	2007
Effect of sulphasalazine and balsalazide on histamine release from mast cells. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2007, Volume: 56 Suppl 1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Gastrointestinal Agents; Histamine Rele	2007
Prescribing of sulfasalazine, azathioprine and methotrexate round pregnancy--a descriptive study. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1 Topics: Antirheumatic Agents; Azathioprine; Databases, Factual; Drug Prescriptions; Drug Therapy, Combinatio	2008
Comparison of the effects of sulphasalazine, 5-aminosalicylic acid and sulphapyridine on the humoral response to antigen in vivo. Advances in experimental medicine and biology, 1995, Volume: 371B Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibo	1995
[5-ASA versus sulfasalazine]. Acta gastroenterologica Latinoamericana, 1994, Volume: 25, Issue:5 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases;	1994
Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents and actions, 1993, Volume: 39, Issue:3-4 Topics: Animals; Colitis; Colon; Eicosanoids; Hydroxyurea; Inflammatory Bowel Diseases; Leukocytes; Lipoxyge	1993
Cyclosporine and 6-mercaptopurine in pediatric inflammatory bowel disease. Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates, 1994, Volume: 16, Issue:4 Topics: Child; Colitis, Ulcerative; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Fema	1994
Desensitization to sulfasalazine. The American journal of gastroenterology, 1993, Volume: 88, Issue:3 Topics: Aminosalicylic Acids; Child; Drug Hypersensitivity; Humans; Inflammatory Bowel Diseases; Stevens-Joh	1993
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 12-1993. A 44-year-old man with pulmonary disease and proctitis. The New England journal of medicine, 1993, Mar-25, Volume: 328, Issue:12 Topics: Adult; Bronchi; Diagnosis, Differential; Eosinophils; Humans; Inflammatory Bowel Diseases; Lung; Mal	1993
New developments: gastroenterology. Current problems in pediatrics, 1993, Volume: 23, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Digestive System; Female; Gastroenterology; H	1993
[A study on interleukin-6 in inflammatory bowel disease]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1993, Volume: 90, Issue:6 Topics: Adolescent; Adult; Aged; Female; Humans; Inflammatory Bowel Diseases; Interleukin-6; Leukocytes, Mon	1993
Co-carcinogenic effect of sulphasalazine. British journal of cancer, 1993, Volume: 68, Issue:5 Topics: 1,2-Dimethylhydrazine; Animals; Carcinogens; Cocarcinogenesis; Dimethylhydrazines; Folic Acid Defici	1993
Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease. European journal of gastroenterology & hepatology, 1995, Volume: 7, Issue:9 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Biopsy; Calcium; Ce	1995
Antibodies in patients with inflammatory bowel disease and the apparent influence of medications. Journal of clinical & laboratory immunology, 1995, Volume: 46, Issue:4 Topics: Adult; Aged; Animals; Antigens, Bacterial; Caseins; Colitis, Ulcerative; Crohn Disease; Food; Gliadi	1995
Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:5 Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N	1996
Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Drug Utilization; Gastrointestinal Ag	1996
Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut, 1996, Volume: 38, Issue:6 Topics: Adult; Biomarkers; Case-Control Studies; Celiac Disease; Chromium Radioisotopes; Cobalt Radioisotope	1996
Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochemical pharmacology, 1997, Jun-15, Volume: 53, Issue:12 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzophenones; Cells, Cultured; Dinoprostone; Gelat	1997
The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men and women with inflammatory bowel disease in Leicestershire. International journal of colorectal disease, 1997, Volume: 12, Issue:4 Topics: Abnormalities, Drug-Induced; Adult; Chronic Disease; Female; Fertility; Humans; Infant, Newborn; Inf	1997
Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scandinavian journal of gastroenterology, 1997, Volume: 32, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Disease; Cross-Sectional	1997
[Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases]. Deutsche medizinische Wochenschrift (1946), 1998, Jan-23, Volume: 123, Issue:4 Topics: Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Chronic Disease; Colitis, Ulcerative; Crohn	1998
Aminosalicylates in the treatment of children with inflammatory bowel disease. Summary of the workshop on aminosalicylate pharmacology. Inflammatory bowel diseases, 1998, Volume: 4, Issue:2 Topics: Adult; Age Factors; Aminosalicylic Acids; Anti-Inflammatory Agents; Child; Digestive System; Dose-Re	1998
Experimental colitis induced by dextran sulphate sodium in mice: beneficial effects of sulphasalazine and olsalazine. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:9 Topics: Aminosalicylic Acids; Animals; Colitis; Dextran Sulfate; Disease Models, Animal; Dose-Response Relat	1998
Inflammatory bowel disease in the pregnant woman. Comprehensive therapy, 1998, Volume: 24, Issue:9 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Breast Feeding; Female; Fertility; Gastrointestinal	1998
Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology, 1998, Volume: 115, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Colon; Epithelial Cells; Gastrointestinal Agents	1998
Effect of DA-6034, a derivative of flavonoid, on experimental animal models of inflammatory bowel disease. Archives of pharmacal research, 1999, Volume: 22, Issue:4 Topics: Acetic Acid; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Anti-Inflammatory Age	1999
Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis. Pharmacogenetics, 2000, Volume: 10, Issue:1 Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Agranulocytosis; Alleles; Anti-Inflammatory	2000
An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2000, Volume: 49, Issue:7 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Humans; Inflammatory Bowel Diseases; Leukemia; Leu	2000
Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. Journal of controlled release : official journal of the Controlled Release Society, 2000, Dec-03, Volume: 69, Issue:3 Topics: Betamethasone; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Humans; Inflammatory B	2000
Population-based case control study of the safety of sulfasalazine use during pregnancy. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:4 Topics: Abnormalities, Drug-Induced; Adult; Case-Control Studies; Female; Gastrointestinal Agents; Humans; I	2001
Glucocorticoids and IL-10, but not 6-MP, 5-ASA or sulfasalazine block endothelial expression of MAdCAM-1: implications for inflammatory bowel disease therapy. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cells, Cultured; Dexameth	2001
[Fatal toxic respiratory epitheliolysis. Subacute tracheo-bronchial desquamation in Stevens-Johnson syndrome]. Revue de pneumologie clinique, 2001, Volume: 57, Issue:4 Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Autopsy; Bronchial Diseases; Bro	2001
Managing the glucocorticoid dependent inflammatory bowel disease patient. Seminars in gastrointestinal disease, 2001, Volume: 12, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antimetabolites; Gastrointestinal A	2001
Mesalamine intolerance mimics symptoms of active inflammatory bowel disease. Journal of pediatric gastroenterology and nutrition, 2002, Volume: 34, Issue:1 Topics: Abdominal Pain; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Humans; Infla	2002
[Inflammatory bowel disease (IBD): development in the area of diagnosis and treatment]. Tijdschrift voor diergeneeskunde, 2002, May-01, Volume: 127, Issue:9 Topics: Adrenal Cortex Hormones; Animal Diseases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diagnosi	2002
Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology, 1978, Volume: 75, Issue:1 Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Humans; Inflammatory B	1978
Ankylosing spondylitis. Current drug treatment. Drugs, 1992, Volume: 44, Issue:4 Topics: Adrenal Cortex Hormones; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Infla	1992
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Alimentary pharmacology & therapeutics, 1992, Volume: 6, Issue:1 Topics: Aminosalicylic Acids; Drug Hypersensitivity; Female; Humans; Inflammatory Bowel Diseases; Male; Mesa	1992
Medical management of inflammatory bowel disease in a spider monkey. Journal of the American Veterinary Medical Association, 1992, May-15, Volume: 200, Issue:10 Topics: Animals; Cebidae; Diarrhea; Electrolytes; Female; Inflammatory Bowel Diseases; Monkey Diseases; Pred	1992
Sulfasalazine desensitization in children and adolescents with chronic inflammatory bowel disease. The American journal of gastroenterology, 1992, Volume: 87, Issue:8 Topics: Adolescent; Aminosalicylic Acids; Child; Chronic Disease; Desensitization, Immunologic; Diarrhea; Do	1992
The effect of therapeutic drugs used in inflammatory bowel disease on the incidence and growth of colonic cancer in the dimethylhydrazine rat model. British journal of cancer, 1992, Volume: 66, Issue:5 Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Cocarcinogenesis; Colonic Neoplasms; Dimethylhydrazin	1992
Sulphasalazine fails to prevent development of mucosal ulceration and 5-lipoxygenase activity in guinea-pigs with chronic inflammatory bowel disease induced by combined bacterial immunization and oral carrageenin. The Journal of pharmacy and pharmacology, 1992, Volume: 44, Issue:6 Topics: Animals; Arachidonate 5-Lipoxygenase; Bacteroides; Carrageenan; Guinea Pigs; Immunization; Inflammat	1992
Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents and actions, 1992, Volume: Spec No Topics: Aminosalicylic Acids; Animals; Disease Models, Animal; Female; Immunization; Inflammatory Bowel Dise	1992
The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel. Acta physiologica Hungarica, 1992, Volume: 80, Issue:1-4 Topics: Free Radical Scavengers; Humans; Hydroxyl Radical; Inflammatory Bowel Diseases; Kinetics; Magnetic R	1992
Inflammatory bowel disease induced by combined bacterial immunization and oral carrageenan in guinea pigs. Model development, histopathology, and effects of sulfasalazine. Digestive diseases and sciences, 1991, Volume: 36, Issue:4 Topics: Animals; Bacteroides; Carrageenan; Disease Models, Animal; Gastric Mucosa; Guinea Pigs; Immunization	1991
[Osteoarticular manifestations of chronic inflammatory enterocolitis]. Annales de gastroenterologie et d'hepatologie, 1991, Volume: 27, Issue:3 Topics: Biopsy; Humans; Inflammatory Bowel Diseases; Spondylitis, Ankylosing; Sulfasalazine	1991
Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clinical and experimental immunology, 1991, Volume: 86, Issue:3 Topics: Adult; Azathioprine; Blood Cell Count; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammat	1991
Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Digestive diseases and sciences, 1991, Volume: 36, Issue:2 Topics: Adult; Aged; Aminosalicylic Acids; Basophils; Cells, Cultured; Colon; Female; Histamine Release; Hum	1991
Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Israel journal of medical sciences, 1990, Volume: 26, Issue:1 Topics: Acetylation; Adolescent; Adult; Aged; Chronic Disease; Dose-Response Relationship, Drug; Female; Hum	1990
Effect of sulfasalazine on spermatogenesis. Fertility and sterility, 1990, Volume: 54, Issue:4 Topics: Humans; Inflammatory Bowel Diseases; Male; Spermatogenesis; Sulfasalazine	1990
Corticosteroid treatment reduces mast cell numbers in inflammatory bowel disease. Digestive diseases and sciences, 1990, Volume: 35, Issue:11 Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Cell Count; Colonoscopy; Humans; Inflammatory Bowel	1990
Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut, 1990, Volume: 31, Issue:12 Topics: Animals; Cell Membrane Permeability; Chromium Radioisotopes; Disease Models, Animal; Edetic Acid; Il	1990
Refractory parastomal ulcers: a multidisciplinary approach. Journal of clinical gastroenterology, 1990, Volume: 12, Issue:6 Topics: Chronic Disease; Colonic Neoplasms; Enterostomy; Female; Humans; Inflammatory Bowel Diseases; Male;	1990
Does proctosigmoiditis in inflammatory bowel disease presage the imminent onset of symptoms? Journal of pediatric gastroenterology and nutrition, 1989, Volume: 8, Issue:3 Topics: Adolescent; Child; Child, Preschool; Colitis; Crohn Disease; Humans; Inflammatory Bowel Diseases; Me	1989
Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology, 1989, Volume: 97, Issue:1 Topics: Acetylation; Aminosalicylic Acids; Chromatography, High Pressure Liquid; Colon; Feces; Humans; Infla	1989
Characterization of sulfasalazine's interference in the measurement of conjugated bilirubin by the Ektachem slide method. Clinical chemistry, 1989, Volume: 35, Issue:8 Topics: Bilirubin; Child; False Positive Reactions; Female; Humans; Inflammatory Bowel Diseases; Spectrophot	1989
Neurofibromatosis and inflammatory bowel disease. Scottish medical journal, 1989, Volume: 34, Issue:4 Topics: Adult; Female; Humans; Inflammatory Bowel Diseases; Middle Aged; Neurofibromatosis 1; Sulfasalazine	1989
Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation. Fertility and sterility, 1989, Volume: 52, Issue:5 Topics: Adult; Aminosalicylic Acids; Animals; Cricetinae; Female; Free Radicals; Humans; Infertility, Male;	1989
Sulfasalazine hypersensitivity with hepatotoxicity, thrombocytopenia, and erythroid hypoplasia. Journal of pediatric gastroenterology and nutrition, 1989, Volume: 9, Issue:2 Topics: Anemia; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child; Drug Hypersensitivity;	1989
The effect of sulphasalazine on the in vitro activation of human peripheral blood mononuclear cells by phytohemagglutinin P. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 1989, Volume: 22, Issue:4 Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Dinoprostone; Humans; In Vitro Techniq	1989
Mesalazine in childhood inflammatory bowel disease. Alimentary pharmacology & therapeutics, 1989, Volume: 3, Issue:6 Topics: Adolescent; Aminosalicylic Acids; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Femal	1989
Sulfasalazine inhibits folate absorption. Nutrition reviews, 1988, Volume: 46, Issue:9 Topics: Anemia, Macrocytic; Colitis, Ulcerative; Folic Acid Deficiency; Humans; Inflammatory Bowel Diseases;	1988

Article	Year
Mud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trial. Joint bone spine, 2007, Volume: 74, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Combined Modality Ther	2007
Antibodies to Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis in the sera of patients with axial and peripheral form of ankylosing spondylitis. British journal of rheumatology, 1995, Volume: 34, Issue:5 Topics: Antibodies, Bacterial; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Humans; Immunoglobulin A	1995
Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. European journal of gastroenterology & hepatology, 2000, Volume: 12, Issue:4 Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Breath Tests; Colitis, Ulcera	2000
Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea. Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:10 Topics: Adult; Aged; Aminosalicylic Acids; Delayed-Action Preparations; Diarrhea; Drug Carriers; Feces; Fema	1992
5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents and actions, 1992, Volume: Spec No Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Animals; Arachidonic Acid; Disease Models, Animal; Do	1992
Influence of sulphasalazine and mesalazine on cellular and biochemical oxygen metabolite production. Effect of in vivo administration and an in vitro analysis. Scandinavian journal of gastroenterology, 1991, Volume: 26, Issue:7 Topics: Aminosalicylic Acids; Double-Blind Method; Humans; In Vitro Techniques; Inflammatory Bowel Diseases;	1991
Aminosalicylates: old and new. The Mount Sinai journal of medicine, New York, 1990, Volume: 57, Issue:5 Topics: Administration, Oral; Aminosalicylic Acids; Enema; Humans; Inflammatory Bowel Diseases; Mesalamine;	1990
Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scandinavian journal of gastroenterology, 1988, Volume: 23, Issue:9 Topics: Adult; Aminosalicylic Acids; Gonadal Steroid Hormones; Humans; Inflammatory Bowel Diseases; Male; Me	1988

sulfasalazine and Bowel Diseases, Inflammatory